Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SA Transcripts 162.21K Followers Follow Rhythm Pharmaceuticals, Inc. ( RYTM ) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 1:50 PM EDT Company Participants David Meeker - Chairman, President & CEO Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Morgan Stanley, Research Division All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the biotech analysts here. And it's my pleasure to introduce David Meeker, President and CEO of Rhythm Pharmaceuticals. And just as a quick reminder, the format for today is a fireside chat. But if anyone in the audience has a question, please raise your hand, and we'll try and address it in our discussion. Before we get started, I just need to read a quick disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. And with that, maybe I'll hand it over to David to make some introductory comments, and thanks for sharing your time with us today. David Meeker Chairman, President & CEO Yes. Thanks, Mike. Yes. So just to set the stage on Rhythm a bit. It's a good moment for the company, for those who are following. We like to set the company framework up, getting people to think about 3 pillars. Obviously, we're working on the melanocortin-4 pathway, our first approved drug IMCIVREE first-generation product was approved in 2020. It's now approved in a couple of genetic, Bardet-Biedl syndrome in 2022 and most recently, HO in the spring of this year. So the 3 pillars we're focused on are a genetic pillar, and we think there's a number of genetic causes of impaired signaling through the melanocortin-4 pathway. We did the EMANATE trial